Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Jitsubo Licenses Peptide Manufacturing Technology to Bachem
May 11, 2020
- Amgen Boosting Repatha Supply System to Gear Up for Praluent Switches
May 11, 2020
- Chugai Begins Joint Research with Singapore Agency on Novel Antibody Drug for COVID-19
May 11, 2020
- 4 Players Join Plasma Alliance to Develop Unbranded Immunoglobulin for COVID-19, Global Study Slated for This Summer
May 11, 2020
- Astellas to Carry on Teleworking through End of May
May 11, 2020
- Takeda’s Entyvio SC Form Approved in Europe
May 11, 2020
- Praluent Barred in Japan after Top Court Nixes Sanofi’s Patent Claim
May 8, 2020
- Daiichi Sankyo Seeks Gastric Cancer Use for Enhertu
May 8, 2020
- Sales Rep Promotions Decrease 34%, Seminars Down 84%: Intage
May 8, 2020
- Akebia/Otsuka's Vadadustat Hits Primary Target in Multinational PIII
May 8, 2020
- Takeda to Maintain Partial Voluntary Ban on Sales Reps Activities in Japan amid Coronavirus Woes
May 8, 2020
- Kyowa Kirin’s Q1 Sales Tick Up as North America Revenue Counters Japan Dip
May 7, 2020
- Fujifilm to Carry Out Process Development, Manufacturing of COVID-19 Treatment for Anti-COVID-19 Initiative
May 7, 2020
- Gilead Files Remdesivir for COVID-19 in Japan
May 4, 2020
- Sanofi Warns of QT Prolongation for Plaquenil after FDA/EMA Flag Risks in COVID-19
May 1, 2020
- Taisho Licenses HIF-PH Inhibitor to US Biotech for Age-Related Diseases
May 1, 2020
- Mitsubishi Tanabe Drops Seasonal Flu Vaccine Project in US, Canadian Plan Intact
April 30, 2020
- Wakamoto, Rohto Forge Comprehensive Biz Tie-Up
April 30, 2020
- Shionogi’s Novel Antibiotic Cefiderocol Approved in Europe
April 30, 2020
- Astellas, Harvard Seal 3-Year Research Alliance Pact
April 30, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…